These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 4732209)
41. Report on the PQRI impurity characterization and quantification best practices survey. Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396 [No Abstract] [Full Text] [Related]
42. The regulation of clinical investigators. Endries RN Food Drug Cosmet Law J; 1980 Jul; 35(7):415-23. PubMed ID: 11661860 [No Abstract] [Full Text] [Related]
43. AIDS and drug pricing: in search of a policy. Salbu SR Wash Univ Law Q; 1993; 71(3):691-734. PubMed ID: 11652750 [No Abstract] [Full Text] [Related]
44. WHO Expert Committee on Specifications for Pharmaceutical Preparations. World Health Organization World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684 [TBL] [Abstract][Full Text] [Related]
45. Cost of HIV drugs. American Public Health Association Am J Public Health; 1991 Feb; 81(2):250. PubMed ID: 11642863 [No Abstract] [Full Text] [Related]
46. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study. Lexchin J Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811 [TBL] [Abstract][Full Text] [Related]
47. Expired drugs are not dead drugs. Torigian PC Am J Hosp Pharm; 1993 Mar; 50(3):448. PubMed ID: 8442459 [No Abstract] [Full Text] [Related]
48. [Quality control of drugs and drug specialties]. Meyrat A Pharm Acta Helv; 1967 Jan; 42(1):14-36. PubMed ID: 6043416 [No Abstract] [Full Text] [Related]
49. Strategy for surveillance of adverse drug events. Bright RA Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403 [No Abstract] [Full Text] [Related]
50. [Nutraceuticals: marketing concept of new science]. Martin A Rev Prat; 2000 Apr; 50(8):817-8. PubMed ID: 10874856 [No Abstract] [Full Text] [Related]
51. Can (or should) the IRB assume the FDA's functions at early stages of the IND process? Levine RJ IRB; 1981 Dec; 3(10):4-5. PubMed ID: 11649414 [No Abstract] [Full Text] [Related]
52. Two new efforts to inform patients about drugs launch a post-PPI era. Med World News; 1982 Sep; 23(20):8-9. PubMed ID: 11645760 [No Abstract] [Full Text] [Related]
53. [Production and control in pharmaceutical industry. Quality control and guarantee of quality. Requirements of IKS-rules in the quality control]. Sahli M; Bircher M Pharm Acta Helv; 1973; 48(8):429-42. PubMed ID: 4766785 [No Abstract] [Full Text] [Related]
54. Development of quality-awareness program for production operators. Barr EG Bull Parenter Drug Assoc; 1975; 29(6):316-9. PubMed ID: 1203610 [No Abstract] [Full Text] [Related]
56. [Observations on drug quality and the QUAD program]. Lalonde M Vie Med Can Fr; 1973 May; 2(5):497-502. PubMed ID: 4732209 [No Abstract] [Full Text] [Related]
57. QUAD routes out inferior drugs. Can Hosp; 1973 May; 50(5):58-9. PubMed ID: 4779804 [No Abstract] [Full Text] [Related]
58. Drug product quality. Exp Med Surg; 1971; 29(1):135-44. PubMed ID: 5147595 [No Abstract] [Full Text] [Related]
59. Quality control of pharmaceutical preparations and the Third World. Summers RS Cent Afr J Med; 1983 Dec; 29(12):247-9. PubMed ID: 6671214 [No Abstract] [Full Text] [Related]
60. 3. Drug regulations in Switzerland and their application. Hippenmeier F Bull Parenter Drug Assoc; 1974; 28(4):167-73. PubMed ID: 4855448 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]